Medicover AB (MCOV.B) AI Stock Analysis

• Market Cap: kr31.95B
• Dividend Yield: 0.66%
• Average Volume (3M): 56.76K
• Price to Earnings (P/E): 42.4
• Beta (1Y): 0.59
• Revenue Growth: 13.89%
• EPS Growth: 231.42%
• Country: SE
• Employees: 47,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 1.38
• Shares Outstanding: 74,428,720
• 10 Day Avg. Volume: 49,170
• 30 Day Avg. Volume: 56,757
• PEG Ratio: -17.99
• Price to Book (P/B): 5.39
• Price to Sales (P/S): 1.20
• P/FCF Ratio: 17.93
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 68 Neutral
• Price Target: kr234.00 ▲(8.33% Upside)

Medicover AB's overall score reflects strong financial performance and positive earnings call guidance, offset by bearish technical indicators and a high P/E ratio. The company's growth trajectory is promising, but high leverage and valuation concerns warrant caution.

Positive Factors

Revenue Growth

Strong revenue growth across multiple regions indicates robust market demand and effective business strategies, supporting long-term expansion.

Cash Flow Generation

Improved cash flow generation enhances financial flexibility, enabling strategic investments and reducing reliance on external financing.

Healthcare Services Expansion

Expansion in healthcare services reflects strong demand and strategic growth, positioning the company well in a competitive market.

Negative Factors

High Leverage

High leverage can increase financial risk and limit flexibility, potentially impacting the company's ability to manage downturns effectively.

Net Profit Margin

Low net profit margins suggest challenges in cost management, which could affect profitability and shareholder returns in the long term.

Impact of Hungary Exit

Exiting the Hungarian market requires strategic adjustments and could temporarily disrupt revenue growth, affecting overall performance.

Medicover AB Business Overview & Revenue Model

Company Description

Medicover AB (MCOV.B) is a leading healthcare and diagnostic services provider based in Sweden. The company operates across various sectors including healthcare services, diagnostics, and health insurance. Medicover offers a wide range of core products and services, such as outpatient and inpatient care, preventive healthcare services, and laboratory diagnostics, catering to both individual patients and corporate clients across Europe and Asia. The company aims to enhance the quality of healthcare through innovative solutions and comprehensive services.

How the Company Makes Money

Medicover AB generates revenue through multiple streams primarily centered around healthcare services and diagnostic solutions. The company earns income from its healthcare facilities, which include hospitals and outpatient clinics, by charging for medical consultations, treatments, and surgeries. Additionally, Medicover generates substantial revenue from its diagnostic services, which encompass laboratory tests and imaging services. The company also offers health insurance products, further diversifying its revenue base. Significant partnerships with corporate clients for occupational health services and collaborations with various healthcare providers enhance its earnings potential. Overall, Medicover's focus on integrated healthcare solutions and a growing demand for quality healthcare services contribute to its financial success.

Medicover AB Financial Statement Overview

Summary

Medicover AB demonstrates strong revenue and cash flow growth, with a TTM revenue increase of 267.96% and free cash flow growth of 262.87%. However, high leverage with a debt-to-equity ratio of 3.05 poses financial risks, and the net profit margin of 1.92% indicates room for improvement in profitability.

Income Statement

Medicover AB shows strong revenue growth with a TTM revenue increase of 267.96%, indicating robust expansion. The gross profit margin of 22.52% and net profit margin of 1.92% reflect stable profitability, although the net margin is relatively low. The EBIT and EBITDA margins of 5.25% and 15.08% respectively, suggest efficient operational management. Overall, the company demonstrates solid growth and profitability, albeit with room for improvement in net margins.

Balance Sheet

The company's debt-to-equity ratio of 3.05 indicates high leverage, which could pose financial risks. However, the return on equity (ROE) of 9.05% shows effective use of equity to generate profits. The equity ratio of 21.71% suggests a moderate reliance on equity financing. While the company is leveraging debt for growth, the high debt levels warrant cautious monitoring.

Cash Flow

Medicover AB's free cash flow growth of 262.87% is impressive, reflecting strong cash generation capabilities. The operating cash flow to net income ratio of 0.52 and free cash flow to net income ratio of 0.56 indicate healthy cash flow relative to earnings. The company demonstrates strong cash flow management, supporting its growth initiatives.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.33B	2.09B	1.75B	1.51B	1.38B	997.80M
Gross Profit	535.87M	448.30M	359.40M	335.60M	395.00M	263.50M
EBITDA	361.81M	171.20M	257.40M	215.90M	274.90M	151.60M
Net Income	67.52M	16.70M	17.60M	11.80M	101.80M	25.80M
Balance Sheet
Total Assets	2.35B	2.14B	1.94B	1.83B	1.68B	1.11B
Cash, Cash Equivalents and Short-Term Investments	83.41M	82.80M	64.40M	49.10M	277.90M	86.80M
Total Debt	1.40B	1.24B	1.00B	940.00M	764.60M	367.40M
Total Liabilities	1.83B	1.65B	1.41B	1.32B	1.12B	627.40M
Stockholders Equity	510.20M	464.80M	496.50M	474.70M	517.60M	448.00M
Cash Flow
Free Cash Flow	154.99M	139.60M	94.50M	29.60M	114.50M	83.50M
Operating Cash Flow	298.18M	261.90M	205.00M	170.20M	216.70M	156.00M
Investing Cash Flow	-313.50M	-134.70M	-119.80M	-184.80M	-333.60M	-126.30M
Financing Cash Flow	34.90M	-108.00M	-73.70M	-24.30M	164.10M	-14.10M

Medicover AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 216.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MCOV.B, the sentiment is Negative. The current price of 216 is below the 20-day moving average (MA) of 216.25, below the 50-day MA of 226.61, and below the 200-day MA of 243.40, indicating a bearish trend. The MACD of -4.18 indicates Negative momentum. The RSI at 37.10 is Neutral, neither overbought nor oversold. The STOCH value of 37.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:MCOV.B.

Medicover AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASKER	77 Outperform	kr30.15B	―	―	―	―	―
ATT	71 Outperform	kr12.66B	19.11	―	1.47%	2.96%	73.50%
HUM	71 Outperform	kr2.63B	10.78	7.53%	2.01%	2.11%	92.69%
MCOV.B	68 Neutral	kr31.95B	42.40	―	0.66%	13.89%	231.42%
AMBEA	65 Neutral	kr10.65B	16.55	13.39%	1.56%	10.83%	16.24%
VIMIAN	64 Neutral	€16.16B	45.71	4.63%	―	17.13%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Medicover AB Corporate Events

Medicover Schedules February 2026 Investor Update in Stockholm

Medicover AB will host an Investor Update in Stockholm on 11 February 2026, where its CEO and CFO will brief investors, analysts and media on the group’s strategy, business performance and key priorities. The English-language event, which will be held both in person and via webcast, underscores the company’s efforts to maintain transparency with capital markets and may provide fresh insight into its operational trajectory and strategic positioning across its core healthcare and diagnostics markets.

The most recent analyst rating on ($SE:MCOV.B) stock is a Hold with a SEK234.00 price target. To see the full list of analyst forecasts on Medicover AB stock, see the SE:MCOV.B Stock Forecast page.

Medicover Reports Strong Q3 2025 Financial Performance

Medicover reported strong financial performance in the third quarter of 2025, with a 12.1% increase in revenue to €591.6 million and a significant rise in operating profit to €42.8 million, driven by improved profitability and efficiency measures. The company’s healthcare services and diagnostic services divisions both saw substantial growth, with notable contributions from operations in Poland and Romania, and the expansion of its network with new hospital openings.

The most recent analyst rating on ($SE:MCOV.B) stock is a Hold with a SEK276.00 price target. To see the full list of analyst forecasts on Medicover AB stock, see the SE:MCOV.B Stock Forecast page.

Medicover’s MRD Assay Shows Promising Results in Lung Cancer Study

Medicover AB announced additional interim results from the DART clinical study at Oslo University Hospital, highlighting the effectiveness of its MRD assay in predicting disease progression in non-small cell lung cancer. The study, presented at the European Society for Medical Oncology Congress, strengthens the clinical validation of Medicover’s MRD assay, marking a significant step towards its commercialisation in 2026 and expansion into other therapeutic areas.

The most recent analyst rating on ($SE:MCOV.B) stock is a Hold with a SEK267.00 price target. To see the full list of analyst forecasts on Medicover AB stock, see the SE:MCOV.B Stock Forecast page.

Medicover AB to Announce Q3 2025 Financial Results

Medicover AB has announced that it will release its Q3 2025 financial report on November 5, 2025. The company will host a conference call for media, financial analysts, and investors, where CEO John Stubbington and CFO Anand Patel will present the report, followed by a Q&A session. This announcement is significant as it provides stakeholders with insights into the company’s financial performance and strategic direction.

The most recent analyst rating on ($SE:MCOV.B) stock is a Hold with a SEK267.00 price target. To see the full list of analyst forecasts on Medicover AB stock, see the SE:MCOV.B Stock Forecast page.